News & Events

Society News Now

News Briefs

RSS ASCLS eNewsBytes

  • Any COVID infection leaves strong antibody levels in kids July 26, 2021
    Even a mild or asymptomatic case of COVID-19 triggers a strong antibody response in children and teens, new research shows. "These findings are encouraging, especially because we cannot yet vaccinate children under the age of 12 against the virus," said study co-lead author Jillian Hurst, an assistant professor in the Department of Pediatrics at Duke […]
  • CDC advisory panel to consider third COVID-19 shot for immunocompromised July 26, 2021
    The Centers for Disease Control and Prevention’s vaccine advisory panel will consider a third COVID-19 shot for immunocompromised individuals. The panel will meet on July 22 to discuss “clinical considerations for additional doses in immunocompromised individuals,” the meeting’s agenda states. Heavy debate around a third COVID-19 shot sparked last week after Pfizer said it would […]
  • Chronic lung disease causes severe COVID-19 infections July 26, 2021
    A new study from the Translational Genomics Research Institute suggests that the airway cells of those with chronic lung disease are primed for COVID-19 infection, meaning that COVID-19 infection in those patients could result in more severe symptoms, poor outcomes and even death. The study outlines the genetic changes caused by chronic lung disease in […]
  • Scientists reverse age-related memory loss in mice July 26, 2021
    Scientists have successfully reversed age-related memory loss in mice and say their discovery could lead to the development of treatments to prevent memory loss in people as they age.
  • Doctors divided over use of controversial new Alzheimer's drug July 26, 2021
    The controversial new Alzheimer's drug Aduhelm is creating something of a civil war in medicine, as health networks, hospitals, insurers and individual doctors weigh impending discussions with patients about whether they should take the medication. Many doctors believe the U.S. Food and Drug Administration "moved the goalposts" to approve Aduhelm (aducanumab) in early June, and […]